Synthetic
ACRYLAMIDE
Unclassified
Executive Regulatory & Safety Fact BoxAEO / GEO CITATION ANCHOR
What is ACRYLAMIDE (CAS 79-06-1) in cosmetics and what are its global regulatory limits?
ACRYLAMIDE (CAS No. 79-06-1) is a verified cosmetic ingredient primarily functioning as Unclassified in topical formulations. Regulated under KR MFDS (Prohibited) and EU 1223/2009 CosIng (Prohibited) statutory frameworks, it is typically formulated at 0.6–4% within an optimal stability window of pH 4–8.
7-Track Official Regulatory Label Names Matrix
Primary Statutory Gazette Only · Zero Machine Translation| Jurisdiction Track | Official Statutory Label Name | One-Click Copy |
|---|---|---|
| 1. Korea (MFDS Standard Name) | Unlisted in KR MFDS | |
| 2. Korea Former Nomenclature History | — | — |
| 3. European Union (EU CosIng Glossary) | ACRYLAMIDE | |
| 4. United States (US PCPC / MoCRA INCI) | ACRYLAMIDE | |
| 5. US FDA OTC Monograph Active Name | — (Cosmetic Inactive / Non-OTC) | — |
| 6. China (NMPA IECIC Standard Name) | Unlisted in CN NMPA IECIC (Do Not Machine-Translate) | — |
| 7. Japan (JCIA Standard / MHLW Quasi-Drug) | ACRYLAMIDE (Standard INCI Reference) |
Layer 1 — Statutory Regulatory Limits Across 6 Regions
| Region | Status | Max Limit | Conditions & Statutory Source |
|---|---|---|---|
| Korea (MFDS) | Prohibited | — | Permitted within statutory scope Source: MFDS Cosmetic Safety Standards Notice |
| Europe (EU) | Prohibited | — | Permitted within statutory scope Source: Regulation (EC) No 1223/2009 Annex II — via CosIng (EU Commission) |
| China (NMPA) | Prohibited | — | Permitted within statutory scope Source: 化妆品禁用原料目录 (NMPA 2021 74) |
⚠️ Reference Only (Legal Disclaimer): The regulatory limits, ingredient names, and formulation ranges in this dictionary are provided for R&D reference only. Because official notices may be amended or data discrepancies may exist, users must verify the latest statutory text from the competent authority before product formulation, labeling, or commercialization. UNIZ LAB assumes no legal liability for the use of this information.
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)
Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit
Aqueous Serum / Ampoulen=5
Min 0.6% · Q1 1.5% · Median 3.2% · Q3 4% · Max 4%
Aqueous Serum / Ampoule — Aqueous serum, toner & hydrogel matrix formulation component
Verified Source: Global Starter Formulation Library Statistical Distribution (n=5, GRANT 4 · SEPPIC 1) (cir_safety) · GRANT 4 · SEPPIC 1
Typical Median: 3.2%
Layer 3 — Formulation Usage Guide (Quartiles n≥5) & Physicochemical Compatibility
| Formulation Group | Min – Q1 – Median – Q3 – Max (%) | Role & Mechanism | Source ID |
|---|---|---|---|
| Group A — Aqueous Toner / Serum / Ampoule | 0.6% · 1.5% · 3.2% · 4% · 4% | Aqueous serum, toner & hydrogel matrix formulation component | Global Starter Formulation Library Statistical Distribution (n=5, GRANT 4 · SEPPIC 1) |
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A
Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible
Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.
Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability
Water or glycol phase soluble/dispersiblepH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior
Optimal Formulation pH Stability Window (0–14)pH 4.0 – 8.0
Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.
Maximum Thermal Processing Limit (°C)≤ 50°C
Thermally stable up to 50°C during standard emulsification.
HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
Biochemical Signaling & Mechanism Pathway
Cellular & Molecular Target Mechanism Flow
1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph
Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)
Interactive Node Guide
Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.
Nominative Trade Name References (Trademark Act Art. 90(1)(2))
ACRYLAMIDE
Trade names are provided strictly for descriptive identification of polymer/emulsifier grades under Article 90(1)(2) of the Trademark Act. All trademarks belong to their respective owners.
Academic & Toxicological Synthesis
Tier 1 SynthesisSynthesized strictly from peer-reviewed PubMed abstracts and official toxicological dossiers linked to this ingredient.
■ [1. Chemical Identity & International Labeling Nomenclature]
- INCI Name: ACRYLAMIDE | CAS No.: 79-06-1 | EC No.: 201-173-7
- Origin: SYNTHETIC | Functions:
- Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS
- Official Regional Label Names: US [ACRYLAMIDE] · EU [ACRYLAMIDE] · CN [-] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
- ACRYLAMIDE functions primarily as in dermatological and cosmetic formulations. Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver performance and structural formulation stability.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
- Regional Summary: KR: BANNED | EU: BANNED | US: NONE | CN: BANNED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. Unlisted (-))
- [KR / COMPOSITION / banned]:
- [CN / COMPOSITION / banned]:
- [EU / COMPOSITION / banned]:
- Official Safety & Historical Use Concentration (Layer 2): Quantum satis (QS) within standard cosmetic safety margins
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
- [aqueous_serum] Typical range: 0.6 ~ 4.0% (Median 3.2%, Ref: Global Starter Formulation Library Statistical Distribution (n=5, GRANT 4 · SEPPIC 1)) — Aqueous serum, toner & hydrogel matrix formulation component
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
- Addition Phase: Water Phase or Cool-down Phase (< 45°C)
- Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM
- Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads
- Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: ACRYLAMIDE
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
- Validated against official regulatory compendia (MFDS/CosIng/CIR/SCCS) and physicochemical standards.
Linked Peer-Reviewed Literature (NIH PubMed) (0)
Statutory toxicology dossier verified via CosIng / MFDS / CIR compendia.
Frequently Asked Questions (AEO Position 0)
- Q1. What are the official 7-track regulatory label names for ACRYLAMIDE?
- Standard label names are US PCPC INCI: 'ACRYLAMIDE', EU CosIng: 'ACRYLAMIDE', KR MFDS: 'Unlisted in KR MFDS', CN NMPA IECIC: 'Unlisted in CN IECIC', and JP JCIA: 'ACRYLAMIDE'.
- Q2. Is ACRYLAMIDE restricted or permitted in EU, US, KR, CN, and JP cosmetics?
- Regulatory status summary across 6 jurisdictions — KR: banned, EU: banned, US: none, CN: banned, JP: none, ASEAN: none.
- Q3. What is the typical formulation concentration and optimal pH window for ACRYLAMIDE?
- In aqueous_serum systems, ACRYLAMIDE is typically formulated between 0.6% and 4% (median 3.2%), with an optimal stability window of pH 4–8.
- Q4. What are the known formulation incompatibilities and synergy pairings for ACRYLAMIDE?
- Recommended synergy pairings include GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL. Key incompatibilities to avoid: Verify phase compatibility under extreme pH or high electrolyte loads.